Principles and Indications of Endocrine Treatment of Advanced Breast Cancer

  • H. T. Mouridsen
  • T. Palshof
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 71)

Abstract

The systemic treatment available for advanced breast cancer includes chemotherapy and endocrine therapy. With combination chemotherapy remission can be achieved in 50%–70% of cases (Carter, 1976), while the response rate of endocrine ablative or additive therapy is about 30% (Hayward, 1970).

Keywords

Toxicity Estrogen Tamoxifen Progesterone Androgen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmann, D. L., O’Connell, M. J., Hahn, R. C., Bisel, H. F., Lee, R. A., Edmonson, J. H.: An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N. Engl. J. Med. 297, 356–360 (1977)PubMedCrossRefGoogle Scholar
  2. Ansfield, F. J., Davis, H. C., Ellerby, R. A., Ramireg, G.: A clinical trial of megesterol acetate in advanced breast cancer. Cancer 33, 907–910 (1974)PubMedCrossRefGoogle Scholar
  3. Broder, L. E., Tormey, D. C.: Combination chemotherapy of carcinoma of the breast. Cancer Treat. Rev. 1, 183–205 (1974)CrossRefGoogle Scholar
  4. Brunner, K. W., Sonntag, R. W., Alberto, P., Senn, H. J., Martz, G., Obrecht, P., Maurice, P.: Combined chemo- and hormonal therapy in advanced breast cancer. Cancer 39, 2923–2933 (1977)PubMedCrossRefGoogle Scholar
  5. Canellos, G. P., Taylor, S. G., Band, P., Pocock, S.: Combination chemotherapy for advanced breast cancer: randomized comparison with single drug therapy. In: Proceedings of the 11th International Cancer Congress 1974, p. 596Google Scholar
  6. Carter, A., Sedransk, N., Kelley, R. M., Ansfield, F. J., Raudin, R. G., Talley, R. W., Potter, N. R.: Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. A Report of the Cooperative Breast Cancer Group. JAMA 237, 2079–2085 (1977)PubMedCrossRefGoogle Scholar
  7. Carter, S. K.: Integration of chemotherapy into combined modality treatment of solid tumors. VII. Adenocarcinoma of the breast. Cancer Treat. Rev. 3, 141–175 (1976)PubMedCrossRefGoogle Scholar
  8. Cooperative Breast Cancer Group: Results of studies of the cooperative breast cancer group 1961–1963. Cancer Chemother. Rep. 41, 1–24 (1964)Google Scholar
  9. Council on Drugs. Subcommittee on Breast and Genital Cancer, Committee on Research, American Medical Association: Androgens and estrogens in the treatment of disseminated mammary carcinoma; retrospective study of 944 patients. JAMA 172, 1271–1284 (1960)CrossRefGoogle Scholar
  10. Dæhnfeldt, J. D., Palshof, T., Mouridsen, H. T.: Biochemical characterization of human breast cancer tissue by the determination of steroid receptor protein and cellular proteins under possible hormonal regulation. In: Reviews in endocrine related cancer. Mayer, M., Saez, S., Stoll, B. A. (eds.), p. 76. 1978Google Scholar
  11. Goldenberg, I. S.: Clinical trials of testolactone, medroxyprogesterone-acetate and oxylone acetate in advanced female mammary cancer. A report of the Cooperative Breast Cancer Group. Cancer 23, 109–111 (1969)PubMedCrossRefGoogle Scholar
  12. Hayward, J.: Hormones and human breast cancer. Recent Results in Cancer Research, Vol. 24. Berlin, Heidelberg, New York: Springer 1970Google Scholar
  13. Kennedy, B. J., Yarbro, J. W.: Effect of methenolone enenthate in advanced cancer of the breast. Cancer 21, 197–201 (1968)PubMedCrossRefGoogle Scholar
  14. Legha, S. S., Carter, S. K.: Antiestrogens in the treatment of breast cancer. Cancer Treat. Rev. 3, 205–217 (1976)PubMedCrossRefGoogle Scholar
  15. Lemkin, R., Dollinger, M. R.: Combination versus single drug therapy in advanced breast cancer. Proc. Am. Ass. Cancer Res. 14, 37 (1973)Google Scholar
  16. Lippman, M. E., Allegra, J. C., Thompson, E. B., Simon, R., Barlock, A., Green, L., Huff, K. K., Hoan, T. D., Aitken, S. C., Warren, R.: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298, 1223–1228 (1978)PubMedCrossRefGoogle Scholar
  17. McGuire, W. L., Carbone, P. P., Vollmer, E. W. (eds.): Estrogen receptors in human breast cancer. New York: Raven 1975Google Scholar
  18. McGuire, W. L., Raynaud, J.-P., Baullieu, E.-E. (eds.): Progesterone receptors in normal and neoplastic tissues. New York: Raven 1977Google Scholar
  19. Mouridsen, H. T., Palshof, T., Brahm, M., Rahbek, I.: Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat. Rep. 61, 47–50 (1977)PubMedGoogle Scholar
  20. Mouridsen, H. T., Palshof, T., Jensen, H. S., Kristensen, D., Rose, C.: Evaluation of oophorectomy plus single drug versus oophorectomy plus multiple drug chemotherapy in the treatment of advanced breast cancer in premenopausal women (in preparation)Google Scholar
  21. Mouridsen, H. T., Palshof, T., Patterson, J., Battersby, L.: Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 5, 131–141 (1978)PubMedCrossRefGoogle Scholar
  22. Muggia, F. M., Cassileth, P. A., Ochoa, M., Flatow, F. A., Gellhorn, A., Hyman, G. A.: Treatment of breast cancer with medroxyprogesteroneacetate. Ann. Intern. Med. 68, 328–337 (1968)PubMedGoogle Scholar
  23. Panutti, F., Martoni, A., Lenaz, G. R., Piana, E., Nanni, P.: Management of advanced breast cancer with medroxyprogesteroneacetate in high doses. Funct. Explor. Sen. 253–256 (1976)Google Scholar
  24. Rubens, R. D., Knight, R. K., Hayward, J. L.: Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br. J. Cancer 32, 730–736 (1975)PubMedCrossRefGoogle Scholar
  25. Segaloff, A., Cuningham, M., Rice, B. F., Weeth, J. B.: Hormonal therapy in cancer of the breast. XIV. Effect of corticosterone or medroxyprogesterone-acetate on the clinical course and hormonal excretion. Cancer 20, 1673–1688 (1967)PubMedCrossRefGoogle Scholar
  26. Stoll, B. A.: Progestin therapy of breast cancer: Comparison of agents. Br. Med. J. 1967 III, 338–341CrossRefGoogle Scholar
  27. Van Dyke, J.-J., Falkson, G.: Extended survival and remission rates in metastatic breast cancer. Cancer 27, 300–303 (1971)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • H. T. Mouridsen
    • 1
  • T. Palshof
    • 1
  1. 1.Finsen Institute, RII-RVCopenhagen ØDenmark

Personalised recommendations